title: Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-α treatment.
abstract: Tumor necrosis factor (TNF)-α is a pro-inflammatory cytokine associated with psoriasis pathogenesis. Anti-TNF-α therapies are effective in psoriasis. A significant weight gain has been reported in patients treated with anti-TNF-α agents. The aim of the present study was to evaluate the body composition changes in psoriatic patients receiving anti-TNF-α therapies according with disease phenotype. Forty patients affected with psoriasis were followed up for 24 weeks and divided into two groups: psoriasis vulgaris (PsO) and psoriatic arthritis (PsA). Anthropometric, blood biochemical, body composition parameters, resting metabolic rate, and disease activity indexes were measured at baseline and at week 24. After 24 weeks of anti-TNF-α administration, the disease activity indexes and concentration of inflammatory markers were significantly decreased. Seventy-five percent of PsO and 60% of PsA patients had an increase in body weight. Weight changes correlated with fat mass gain in the PsO group, and with fat and lean mass gain in the PsA group. In the present study, we demonstrated that a blockage of TNF-α bioactivity is related with fat and lean mass gain in both PsO and PsA subjects. The anti-TNF-α therapies could play a key role in the cross talk between adipose tissue and skeletal muscle, mediated by the reduction of TNF-α and interleukin-6 production.
authors.affiliation: Division of Human Nutrition, Department of Neuroscience, University of Rome Tor Vergata, Italy.
authors.forename: Laura D I
authors.initials: LD
authors.lastname: Renzo
authors.forename: Rosita
authors.initials: R
authors.lastname: Saraceno
authors.forename: Caterina
authors.initials: C
authors.lastname: Schipani
authors.forename: Mariagiovanna
authors.initials: M
authors.lastname: Rizzo
authors.forename: Alessia
authors.initials: A
authors.lastname: Bianchi
authors.forename: Annalisa
authors.initials: A
authors.lastname: Noce
authors.forename: Maria
authors.initials: M
authors.lastname: Esposito
authors.forename: Sergio
authors.initials: S
authors.lastname: Tiberti
authors.forename: Sergio
authors.initials: S
authors.lastname: Chimenti
authors.forename: Antonino
authors.initials: A
authors.lastname: DE Lorenzo
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D001823:Body Composition / Q000187:drug effects*; D001835:Body Weight / Q000187:drug effects*; D000068800:Etanercept; D005500:Follow-Up Studies; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use; D000069285:Infliximab; D008875:Middle Aged; D011446:Prospective Studies; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept